Article

Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.

Division of Endocrinology, Hypertension and Diabetes, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, Boston, Mass 02115, USA.
Circulation (Impact Factor: 15.2). 12/2003; 108(20):2517-23. DOI: 10.1161/01.CIR.0000097000.51723.6F
Source: PubMed

ABSTRACT Angiotensin II (Ang II) increases levels of aldosterone and plasminogen activator inhibitor-1 (PAI-1). Both aldosterone and PAI-1 seem to promote cardiovascular (CV) injury. Our objective was to determine the roles of PAI-1 and aldosterone in the development of myocardial and renal damage in a model with high Ang II and low nitric oxide (NO) availability, a pattern seen in patients with heart failure, diabetes mellitus, and arteriosclerosis.
Mice on a moderately high sodium diet were treated with the NO synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) for 14 days plus Ang II during days 8 through 14. The roles of aldosterone and PAI-1 in the development of CV injury were assessed using the mineralocorticoid receptor antagonist spironolactone (0, 1.5, 15, and 50 mg x 100 g(-1) x day(-1)) and PAI-1-deficient mice (PAI-1-/-). Ang II/L-NAME-treated mice showed glomerular ischemia, proteinuria, and necrosis of myocytes and vascular smooth muscle cells with an associated mixed inflammatory response, deposition of loose collagen, and neovascularization. Compared with saline-drinking mice, Ang II/L-NAME-treated mice had significantly increased heart to body weight (HW/BW) ratios, cardiac and renal damage assessed by histological examination, PAI-1 immunoreactivity, and proteinuria. Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage. PAI-1-/- animals had a similar degree of CV injury as PAI-1+/+ animals.
Mineralocorticoid receptor antagonism, but not PAI-1 deficiency, protected mice from developing Ang II/L-NAME-mediated myocardial and vascular injury and proteinuria, suggesting that aldosterone, but not PAI-1, plays a key role in the development of early Ang II/L-NAME-induced cardiovascular injury.

0 Bookmarks
 · 
35 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrixmetalloproteinasen beeinflussen die Entstehung, die Progression und die Komplikationen der Atherosklerose. Sie spielen eine wichtige Rolle beim Abbau der vaskulären Basalmembran und der Extrazellularmatrix. Vermutlich sind sie über diese Mechanismen und über die Beeinflussung der Endothelzellbarriere wesentlich an der Pathogenese der Atherosklerose beteiligt. Im ersten Teil der Arbeit beschäftigten wir uns mit der Frage, ob MMPs durch Endothelzellen gebildet werden können. Bei unseren Versuchen konnten wir die Präsenz von MMP-2 und MMP-9 im Überstand von humanen Nabelschnurvenenendothelzellen (HUVECs) nachweisen. Somit sind menschliche Endothelzellen direkt an der lokalen Produktion von MMPs beteiligt. Im zweiten Teil der Arbeit wurde untersucht, wie MMP-2 in den Nabelschnurendothelien gebildet und reguliert wird. MMP-2 wird in Endothelzellen zeitabhängig sezerniert. Bradykinin führt dosisabhängig zu einer gesteigerten pro-MMP-2 Sekretion. Bei der Stimulation mit PMA und Interleukin 1-beta wird demgegenüber vermehrt intermediäres und aktives MMP-2 im Überstand detektiert. Nach der Vorbehandlung der Zellen mit dem Proteinsynthesehemmer Cycloheximid war nach 24 Stunden nahezu kein pro-MMP-2 mehr im Überstand der Endothelzellkulturen nachweisbar. Das Tubulusgift Colchicin führte zu einer signifikanten Verringerung der freigesetzten pro-MMP-2 Menge. Es ließ sich jedoch noch eine geringe Menge an intermediären und aktiven MMP-2 nachweisen. In weiteren Experimenten sollte untersucht werden, ob die Komponenten des Renin-Angiotensin-Aldosteron Systems, welche als wichtige Faktoren in der Pathogenese der Atherosklerose diskutiert werden, die endotheliale Synthese und Freisetzung von MMP-2 regulieren. Dabei zeigte sich, dass Aldosteron einen signifikanten stimulatorischen Effekt auf die pro-MMP-2 Menge im Überstand der HUVECs besitzt. Im Gegensatz dazu ließ sich bei der Stimulation der Endothelzellen mit Angiotensin II nur eine tendenziell vorhandene Erhöhung der Angiotensin II induzierten MMP-2 Bildung nachweisen. Zusammenfassend ist von einer Beeinflussung der endothelialen MMP-Bildung durch Komponenten des RAAS auszugehen. Die geringe Stimulierbarkeit der endothelialen MMP und die hohe interexperimentelle Variabilität der MMP-Bildung lassen jedoch keine abschließende Bewertung zu. In Zukunft wird es sicherlich notwendig sein, weitere Studien (evtl. mit molekularbiologischen Ansätzen) zur näheren Charakterisierung des Zusammenhanges zwischen RAAS und der MMP-Bildung in HUVECs durchzuführen. Matrixmetalloproteinases play an important role in the formation, progression and the complications of atherosclerosis. Likely, Matrixmetalloproteinases are involved in the pathogensis of atherosclerosis by influencing the endothelial barrier by decomposing the basalmembrane and the extracellular matrix. It´s questionable whether endothelial cells produce MMPs and whether the renin-angiotensin-aldosterone system, which is presumed to play a role in the pathogenesis of atherosclerosis, could influence this production. In the first step of this study we detected the gelatinaes MMP-2 and MMP-9 in conditioned medium of HUVECs (human umbilical vein endothelial cells). Zymographic analysis revealed gelatinolytic activity at 72 (pro-MMP-2), 64 (intermediate MMP-2) and 62 kD (active MMP-2). The treatment of HUVECs with bradykinin led to an increased secretion of pro-MMP-2. When we stimulated HUVECs with PMA as well as IL-1β, there was an increased appearence of intermediate and active MMP-2 in the conditioned medium. After the incubation with Cycloheximide, a proteinsynthesis inhibitor, little pro-MMP-2 was found. That means, that most of pro-MMP-2 must have been syntheticized de-novo and that only a few Proteinases were already ready for secretion in vesicels. The transport of these vesicles can be hindered with Colchicin. In the next step we investigated the influence of the renin-angiotensin-aldosterone-system upon the endothelial MMP-2. Aldosterone led to an increased appearence of pro-MMP-2 in the conditioned medium. In contrast to that we found only a tendency of increased pro-MMP-2 in the angiotensin II conditioned medium. In summary we proceed from the assumption that the RAA-System could influence the endothelial MMP-Production. However the low ability to stimulate the endothelial MMP and the high interexperimentel variability don´t allow a final valuation. In the future it will be necessary to carry out more studies to characterize the correlation between MMPs and the renin-angiotensin-aldosterone system.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether mineralocorticoid receptor (MR) activation plays a role in diabetic renal injury and whether this role differs in types 1 and 2 diabetes mellitus, we examined the effect of a MR antagonist on renal injury in rodent models of type 1 (streptozotocin-treated rat) and type 2 (db/db mouse) diabetes. We studied three groups of 8-wk-old, uninephrectomized Wistar rats for 4 wk: diabetic streptozotocin- (55 mg/kg) treated rats (n = 11), diabetic streptozotocin-treated rats receiving the MR antagonist eplerenone (n = 15), and nondiabetic rats (n = 9). In addition, we studied three groups of 8-wk-old mice for 16 wk: diabetic db/db mice (n = 10), diabetic db/db mice treated with eplerenone (n = 8), and nondiabetic, db/+ littermates (n = 11). Diabetic rats and mice developed albuminuria and histopathological evidence of renal injury, including glomerular hypertrophy, mesangial expansion, and tubulointerstitial injury as well as increased renal cortical levels of MR protein, MR mRNA, TGFbeta mRNA, and osteopontin mRNA. All of these changes were significantly reduced by treatment with eplerenone except for the elevated MR levels. The beneficial effects of eplerenone were not attributable to changes in blood pressure or glycemia. In summary, MR expression was increased in kidneys of diabetic rodents, and MR antagonists effectively reduced diabetic renal injury irrespective of the species or specific cause of the diabetes. Thus, these data suggest that MR activation is a critical factor in the early pathogenesis of renal disease in both type 1 and type 2 diabetes mellitus.
    Endocrinology 12/2006; 147(11):5363-73. · 4.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a striking consistency in the total number of heart beats accrued over a lifetime across a range of animal species despite vast differences in size. Moreover, an inverse relationship is observed between heart rate and lifespan, leading to speculation that elevated heart rate could significantly affect longevity. It is the aim of this review to analyze heart rate as a contributing factor in defining the functional lifespan of the transplanted human heart, which may unavoidably determine the longevity of the recipient. Sinus tachycardia occurs as a result of sympathetic/parasympathetic denervation, an unavoidable consequence of transplantation. The effect of elevated heart rate in this cohort has been scarcely reported. We highlight herein multitudinous mechanisms whereby elevated heart rate accelerates the deterioration in cardiac function and arterial elasticity due to injury and stress accumulation. Additionally, we propose a significant role for heart rate in confounding the alloimmune response. Tachycardia exacerbates injurious episodes of myocardial ischemia and significantly increases the production of reactive oxygen species via increased metabolism. These factors promote immune infiltration and activation, contributing to acute and chronic rejection. Further research is required to assess the potential therapeutic benefits of heart rate reduction.
    Transplantation 10/2012; · 3.78 Impact Factor